Author

R. L. V. Mercuri

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Approach:statistical model· 2 Assay:ATAC-seq· 1 Approach:biophysical modeling· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

P. A. F. Galante· 2 shared A. Savio· 1 shared D. M. Mombach· 1 shared E. L. S. Loreto· 1 shared F. M. Meliso· 1 shared G. D. A. Guardia· 1 shared H. B. Conceicao· 1 shared J. Ule· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

P. A. F. Galante

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The paralogues MAGOH and MAGOHB are oncogenic factors in high-grade gliomas and safeguard the splicing of cell division and cell cycle genes

R. A. S. Barreiro, G. D. A. Guardia, F. M. Meliso, X. Lei, A. Savio, M. Fellermeyer, H. B. Conceicao, R. L. V. Mercuri, T. Landry, M. Qiao, L. Blazquez, J. Ule, L. O. Penalva, P. A. F. Galante

This study identifies MAGOH and MAGOHB as oncogenic factors in high-grade gliomas that safeguard splicing of cell division and cell cycle genes, with high expression linked to poor prognosis.

RNA Biology · Dec 31, 2023Peer-reviewedCancer Biology

TRANSPOSABLE ELEMENTS ALTER GENE EXPRESSION AND MAY IMPACT RESPONSE TO CISPLATIN THERAPY IN OVARIAN CANCER

D. M. Mombach, R. L. V. Mercuri, T. M. F. F. Gomes, P. A. F. Galante, E. L. S. Loreto

This study investigates how transposable elements (TEs) affect gene expression and response to cisplatin therapy in ovarian cancer cell lines.

bioRxiv · Sep 29, 2023Cancer Biology